drugset
drugset / Trial / NCT01572519

A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01572519 ↗

Phase 1 Completed 21 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety, pharmacokinetics, and preliminary efficacy information of JNJ-40346527 in patients with relapsed or refractory Hodgkin lymphoma.

Timeline

Start
2012-07-17
Primary completion
2013-08-13
Completion
2013-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-40346527 Unknown 150 mg Oral
Subject JNJ-40346527 Unknown 300 mg Oral
Subject JNJ-40346527 Unknown 450 mg Oral
Subject JNJ-40346527 Unknown 600 mg Oral

Indications

Hodgkins lymphoma